Moving towards personalized medicine in MDS

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the future of treatment for patients with myelodysplastic syndromes (MDS), emphasizing that the main paradigm shift will be towards a more personalized system. The findings of several ongoing, large scale clinical trials investigating the combination of hypomethylating agents with novel therapies will likely have a significant impact on the standard of care in MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.